Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients.

ESMO open·2022
Same author

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.

ESMO open·2021
Same author

Acute hantavirus infection presenting as haemolytic-uraemic syndrome (HUS): the importance of early clinical diagnosis.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use.

Journal of immunology research·2017
Same author

Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium.

Leukemia research·2016
Same author

Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?

Multiple sclerosis (Houndmills, Basingstoke, England)·2013
Same journal

MEFV variants as phenotypic modifiers in ankylosing spondylitis: a genetic interaction analysis with HLA-B27.

Acta clinica Belgica·2026
Same journal

What Europe should (not) learn from the new Dietary Guidelines for Americans.

Acta clinica Belgica·2026
Same journal

Real-world evidence on In-hospital statin use and mortality in geriatric patients.

Acta clinica Belgica·2026
Same journal

TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer.

Acta clinica Belgica·2026
Same journal

A decade of insulin pump therapy in a Belgian paediatric diabetes centre: longitudinal outcomes and evolving practices.

Acta clinica Belgica·2026
Same journal

Pneumococcal vaccination in Belgian adults: a practical translation of the 2025 Superior Health Council guidelines.

Acta clinica Belgica·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Immunotherapy in leukaemia.

A L R Van De Velde1, S Anguille, Z N Berneman

  • 1Antwerp University Hospital, Division of Haematology, Edgem, Belgium. Ann.Van.De.Velde@uza.ba

Acta Clinica Belgica
|January 24, 2013
PubMed
Summary
This summary is machine-generated.

Therapeutic cancer vaccines using dendritic cells (DCs) educate the immune system to fight cancer. WT1 mRNA-transfected DCs show promise for controlling acute myeloid leukaemia (AML) and preventing relapse.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: May 14, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

  • Oncology
  • Immunology
  • Cancer Vaccinology

Background:

  • Therapeutic cancer vaccination is an emerging oncology treatment.
  • Dendritic cells (DCs) present tumour antigens to educate the immune system.
  • DC-based immunotherapy stimulates innate (NK) and adaptive (T cell) responses, correlating with clinical benefit.

Purpose of the Study:

  • To evaluate WT1 mRNA-transfected DCs as a therapeutic cancer vaccine strategy.
  • To assess the efficacy of this approach in controlling residual disease in acute myeloid leukaemia (AML).
  • To explore its potential as a post-remission treatment to prevent relapse.

Main Methods:

  • Utilizing WT1 mRNA-transfected dendritic cells (DCs) for cancer vaccination.
  • Administering DCs to 'educate' the immune system to recognize and attack tumour cells.
  • Implementing this strategy as a post-remission treatment in AML patients.

Main Results:

  • WT1 mRNA-transfected DCs represent a feasible strategy for controlling residual disease in AML.
  • This approach effectively leverages the immune system's potential to eradicate malignant cells.
  • The immunotherapy elicits both innate and adaptive cellular responses linked to clinical benefit.

Conclusions:

  • WT1 mRNA-transfected DC-based immunotherapy is a promising strategy for AML treatment.
  • It offers a novel approach for post-remission care to prevent relapse.
  • This method harnesses the immune system for effective cancer eradication.